CJC-1295 research followed hormones, not daily health
Human studies checked IGF-1 and growth hormone after a shot. They didn't prove better sleep, strength, weight, or safety over time.
CJC-1295 made the growth gland send out more hormone
ConjuChem, a drug company, built CJC-1295 to keep one of the brain's brief orders working longer. The growth gland answered by sending growth hormone into your blood.
Scientists call the natural order growth hormone-releasing hormone. CJC-1295 is a lab-made copy that reaches the gland and starts hormone release [2].
Growth hormone then prompts the liver to make IGF-1, a second hormone tied to growth [2]. A higher IGF-1 blood reading doesn't tell you whether a person feels well.
CJC-1295 doesn't put outside growth hormone into your body. It prompts your own gland, and researchers then check what appears in blood.
In human volunteers, the gland kept the short bursts your body normally uses. The drug didn't turn those bursts into a steady stream [3], so your body's usual timing remained.
Four changes slowed the breakdown of CJC-1295
Scientists changed protein parts numbered 2, 8, 15 and 27. The body then broke the copy down more slowly [2].
On CJC-1295 DAC, a hook catches albumin as that protein moves through blood. Albumin carries the hooked drug longer [2], which is the point of DAC.
Rats given the hooked version released 4-fold more growth hormone over two hours. After 72 hours, blood tests could still detect it [2].
Those were rat results, so they can't say how you would feel. A 2025 review grouped CJC-1295 with sermorelin, a shorter copy, and tesamorelin, a copy approved to reduce deep belly fat in some adults with HIV [12].
The long form remained in blood for several days
An early study enrolled healthy adults from ages 21 to 61, so it tells you about volunteers in good health rather than patients being treated for an illness in that trial. Each person got 30 or 60 micrograms per kilogram through a shot into the fat layer beneath the skin.
Each microgram is a millionth part of one gram. Per kilogram means the amount changed with body weight, so this wasn't one flat amount for everyone.
Average growth hormone rose 2- to 10-fold from its starting point. IGF-1, the liver-made hormone, rose as well and stayed high longer [1].
After repeat shots, IGF-1 was still higher than the first reading for up to 28 days. Blood tests showed 5.8 to 8.1 days passed before half the drug was gone [1].
Half the long CJC-1295 dose was gone after 5.8-8.1 days
That time belongs only to the long DAC form. Modified GRF (1-29), the short no-DAC form, can't attach to albumin.
The short form may leave in minutes or hours [8]. In an earlier study of healthy men, researchers found that the brain's natural message also disappeared within minutes [9].
Another study tested a different way to make this kind of hormone copy last longer [10]. It helps explain what scientists were trying, but adds no proof about CJC-1295 or anyone's health.
The blood changes didn't show a health gain
A shot led to roughly 45% more IGF-1 after a week [3]. The study didn't show that those healthy adults slept better, grew stronger, or felt different.
A lasting blood change isn't a tested treatment. No approved amount has been set for any illness, so these figures aren't a care plan for you.
Healthy men had an IGF-1 rise and kept usual hormone bursts
The most carefully characterized human finding concerns the pattern of GH release, not just its magnitude. In healthy men aged 20 to 40, a single subcutaneous dose of 60 or 90 micrograms per kilogram raised trough GH approximately 7.5-fold, mean GH by about 46% and IGF-1 by about 45% one week later — while the frequency and magnitude of pulsatile GH secretion were unaltered [3]. In other words, the GH axis kept its natural pulse-like rhythm even under sustained stimulation.
What the Research Reports: GH and IGF-1 Responses
That preserved pulsatility is a meaningful result, because continuous, non-pulsatile GH elevation is generally considered less physiological. A separate proteomic study in 11 healthy young men found reproducible serum protein changes after CJC-1295 — decreased apolipoprotein A1 and a transthyretin isoform, increased albumin-fragment and immunoglobulin species — with one signal correlating linearly with IGF-1, identifying candidate biomarkers of GH/IGF-1 axis activation [4]. In GHRH-knockout mice, 2 micrograms once every 24 hours fully normalized body weight and length, whereas dosing every 48 to 72 hours was progressively less effective, and treatment raised pituitary GH mRNA [6].
Numbers from CJC-1295 experiments answer a laboratory question, not whether a person is a treatment candidate; where peptide treatment requires a prescription, Promise Peptides (mypromise.com) uses telehealth review by licensed clinicians, a different process from reading a hormone-response study.
Does CJC-1295 and ipamorelin work?
Mechanistically, GHRH analogs and growth-hormone-releasing peptides act on different receptors, and co-administration produces GH release greater than either alone [11]. Controlled efficacy data for the specific CJC-1295/ipamorelin pairing in healthy adults are limited; the rationale is mechanistic, not a validated regimen.
CJC-1295 ipamorelin is an idea that human studies haven't proved
ConjuChem made CJC-1295 to copy one hormone order. Ipamorelin is another lab-made drug that can prompt the growth gland and may also affect hunger [11].
The two drugs reach the gland by different routes inside your body. Together the drugs might produce a larger growth hormone release, but that doesn't show you would feel better [11].
CJC-1295 ipamorelin combines two ways of prompting the gland
The CJC-1295 ipamorelin pair uses both drugs at once. No public agency has cleared the pair for treatment, even though the drugs start hormone release in different ways [11].
That difference gives scientists a question worth testing. It doesn't give you a known benefit, since no sound human study has shown one in healthy adults [11].
Human studies haven't set an amount for the pair
No human study has compared set amounts of this pair well enough to establish a dose. Figures from online posts aren't a tested plan [11].
The way CJC-1295 and ipamorelin act in your body can explain why scientists are curious. It can't supply a safe amount, timing, or health result for you.
CJC-1295, sermorelin, and tesamorelin don't have the same standing
Sermorelin is a shorter-lasting copy of the same brain order. Tesamorelin is approved to reduce extra belly fat in some adults with HIV, while CJC-1295 isn't [12][12].
The CJC-1295 albumin hook makes CJC-1295 DAC remain in blood longer [2]. Yet CJC-1295 reached only early human tests before the later plan stopped [7].
The two compounds in the pairing act on distinct receptor pathways. That rationale is mechanistic, not evidence of a validated human regimen.
The strongest findings are still only blood results
ConjuChem wanted a hormone effect that lasted. More than one study found that the DAC form kept working for days [1][3].
Rats released 4-fold more growth hormone with the hooked form. In mice born without a normal brain order, frequent shots brought growth back to normal [2][6].
Both findings came from animals. For your choice, they cannot predict whether the drug would help or harm you.
No large human study has shown better health from CJC-1295. Strong human proof is also missing for safety over years and for the CJC-1295/ipamorelin pair [7][11].
After one week, the IGF-1 blood reading was 45% higher [3]. That number doesn't say whether the person slept, moved, or felt better.
One report says a lab found CJC-1295 in a seized item sold as a hormone-release product [16]. It doesn't say who seized the item, and one test cannot tell you whether such goods are safe.
Use the FDA and sports answers for the rules that may affect you. The complete source list opens the human and animal reports, including the other IGF-1 finding.